Pure Global
NCT06095115

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
Janssen Research & Development, LLC·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Plaque Psoriasis
Drug/Device/Intervention
JNJ-77242113
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Janssen Research & Development, LLC
Location
Phoenix,Fort Smith,Fountain Valley,Fremont,Macon,Rolling Meadows,Plainfield,Owensboro,Lake Charles,Clarkston,New Brighton,Omaha,East Windsor,Athens,Boardman,Portland,Rapid City,Arlington,San Antonio,M, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Oct 12, 2023
End date
Jun 14, 2027
Enrollment
600 participants
Primary outcome

Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (= )2-Grade Improvement From Baseline to Week 16,Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Summary

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate
 to severe plaque psoriasis.

ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06095115
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06095115 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.